Mối tương quan giữa các chỉ số chuyển hóa của khối u tiên phát với các đặc điểm lâm sàng, mô học và phân tử ở bệnh nhân ung thư vú trong nghiên cứu FDG-PET/CT chuẩn bị phẫu thuật

Rager O, Lee-Felker SA, Tabouret-Viaud C, Felker ER, Poncet A, Amzalag G, Garibotto V, Zaidi H, Walter MA (2018) Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparison. American journal of nuclear medicine and molecular imaging 8(3):159–168 Chandra P et al (2020) Evaluation of diagnostic accuracy and impact of preoperative positron emission tomography/computed tomography in the management of early operable breast cancers. Indian Journal of Nuclear Medicine: IJNM: The Official Journal of the Society of Nuclear Medicine, India 35(1):40 Elsayed AG et al (2018) PET avidity and tumor clinical and pathological features in breast cancer. Proc Am Soc Clin Oncol 36(15_suppl):e12623. https://doi.org/10.1200/JCO.2018.36.15_suppl.e12623 Dai X et al (2015) BCintrinsic subtype classification, clinical use and future trends. Am J Cancer Res 5(10):2929 Surov A, Meyer HJ, Wienke A (2019) Associations between PET parameters and expression of Ki-67 in breast cancer. Transl Oncol 12(2):375–380. https://doi.org/10.1016/j.tranon.2018.11.005 Jafari SH et al (2018) BCdiagnosis: Imaging techniques and biochemical markers. J Cell Physiol 233(7):5200–5213 Segaert I, Mottaghy F, Ceyssens S, de Wever W, Stroobants S, van Ongeval C, van Limbergen E, Wildiers H, Paridaens R, Vergote I, Christiaens MR, Neven P (2010) Additional value of PET–CT in staging of clinical stage IIB and III breast cancer. Breast J 16(6):617–624. https://doi.org/10.1111/j.1524-4741.2010.00987.x Yamamoto S et al (2019) Maximum standardized uptake value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography could replace pathological diagnosis in luminal breast cancer. Annals of Breast Surgery 3. https://doi.org/10.21037/abs.2019.02.01 Turkmen C (2019) Nuclear Medicine Imaging in Breast Cancer. In: Breast Cancer Springer, pp 223–237 Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K (2018) Prognostic value of FDG-PET and DWI in breast cancer. Ann Nucl Med 32(1):44–53. https://doi.org/10.1007/s12149-017-1217-9 Satoh Y, Motosugi U, Omiya Y, Onishi H (2019) Unexpected Abnormal Uptake in the Breasts at Dedicated Breast PET: Incidentally Detected Small Cancers or Nonmalignant Features? Am J Roentgenol 212(2):443–449. https://doi.org/10.2214/AJR.18.20066 Vanderhoek M, Perlman SB, Jeraj R (2012) Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med 53(1):4–11. https://doi.org/10.2967/jnumed.111.093443 Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA (2004) Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 45(9):1519–1527 Keramida G, Dizdarevic S, Bush J, Peters AM (2015) Quantification of tumour 18 F-FDG uptake: Normalise to blood glucose or scale to liver uptake? Eur Radiol 25(9):2701–2708. https://doi.org/10.1007/s00330-015-3659-6 Wahl RL et al (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 50(Suppl 1):122S Lee JW, Kim SK, Lee SM, Moon SH, Kim TS (2011) Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. Mol Imaging Biol 13(3):565–572. https://doi.org/10.1007/s11307-010-0394-x Ali Gholamrezanezhad MD, Muzaffar FR, Osman MM (2012) Respiratory Muscle^ sup 18^ F-FDG Uptake/REPLY. Journal of Nuclear Medicine Technology 40(3):210 Önner H, Canaz F, Dinçer M, Işiksoy S, Sivrikoz İAK, Entok E, Erkasap S (2019) Which of the fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography parameters are better associated with prognostic factors in breast cancer? Medicine. 98(22):e15925. https://doi.org/10.1097/MD.0000000000015925 IBM_SPSS. Statistical Package for Social Science. Ver.21. Standard version. Copyright © SPSS Inc., 2011-2012. NY, USA. 2012 Groheux D et al (2013) Performance of FDG PET/CT in the clinical management of breast cancer. Radiology 266(2):388–405 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the 1ry Therapy of Early BC2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304 Shin S, Pak K, Kim SJ (2016) Tumor heterogeneity assessed by 18F-FDG PET/CT is not significantly associated with nodal metastasis in BCpatients. Oncology research and treatment 39(1-2):61–66. https://doi.org/10.1159/000442760 Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34(3):414–419 Lee SH, Kim SH, Park HS, Kim JH, Kim D, Cho H, Yun M (2019) The prognostic value of 18f-fdg uptake in the supraclavicular lymph node (n3c) on Pet/ct in patients with locally advanced BCwith clinical N3c. Clin Nucl Med 44(1):e6–e12. https://doi.org/10.1097/RLU.0000000000002365 Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H (2008) Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in 1ry breast cancer. Jpn J Clin Oncol 38(4):250–258. https://doi.org/10.1093/jjco/hyn019 Abubakar ZA, Akepati NKR, Bikkina P (2019) Correlation of maximum standardized uptake values in 18F-Fluorodeoxyglucose positron emission tomography-computed tomography scan with immunohistochemistry and other prognostic factors in breast cancer. Indian Journal of Nuclear Medicine: IJNM: The Official Journal of the Society of Nuclear Medicine, India 34(1):10 Alavi J (2019) 18 Utility of F-FDG PET/CT in pre-surgical risk stratification of patients with breast cancer. Hellenic journal of nuclear medicine 22(3):165–171 Antunovic L, Gallivanone F, Sollini M, Sagona A, Invento A, Manfrinato G, Kirienko M, Tinterri C, Chiti A, Castiglioni I (2017) [18 F] FDG PET/CT features for the molecular characterization of 1ry breast tumors. Eur J Nucl Med Mol Imaging 44(12):1945–1954. https://doi.org/10.1007/s00259-017-3770-9 Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E (2011) Correlation of high 18 F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38(3):426–435. https://doi.org/10.1007/s00259-010-1640-9 Higuchi T, Nishimukai A, Ozawa H, Fujimoto Y, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, Kitajima K, Fukushima K, Miyoshi Y (2016) Prognostic significance of preoperative 18F-FDG PET/CT for BCsubtypes. Breast 30:5–12. https://doi.org/10.1016/j.breast.2016.08.003 Ishiba T, Nakagawa T, Sato T, Nagahara M, Oda G, Sugimoto H, Kasahara M, Hosoya T, Kubota K, Fujioka T, Danenberg P, Danenberg K, Uetake H (2015) Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in BCpatients received neoadjuvant chemotherapy. SpringerPlus 4(1):817. https://doi.org/10.1186/s40064-015-1634-y Kaida H, Toh U, Hayakawa M, Hattori S, Fujii T, Kurata S, Kawahara A, Hirose Y, Kage M, Ishibashi M (2013) The relationship between 18F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancer. Nucl Med Commun 34(6):562–570. https://doi.org/10.1097/MNM.0b013e328360d945 Kajáry K, Tőkés T, Dank M, Kulka J, Szakáll S, Lengyel Z (2015) Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer. Nucl Med Commun 36(1):28–37. https://doi.org/10.1097/MNM.0000000000000217 Koo HR, Park JS, Kang KW, Han W, Park IA, Moon WK (2015) Correlation between 18 F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur Radiol 25(11):3314–3321. https://doi.org/10.1007/s00330-015-3734-z Tuzcu SA et al (2020) The association of axillary lymph node-positive BC with metabolic parameters of 18F-fluorodeoxyglucose PET/CT. Medical Science and Discovery 7(3):445–449. https://doi.org/10.36472/msd.v7i3.363 Yildirim N, Simsek M, Aldemir MN, Bilici M, Tekin SB (2019) Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers. The Eurasian journal of medicine 51(2):154–159. https://doi.org/10.5152/eurasianjmed.2018.18036 Sanli Y, Kuyumcu S, Ozkan ZG, Işık G, Karanlik H, Guzelbey B, Turkmen C, Ozel S, Yavuz E, Mudun A (2012) Increased FDG uptake in BC is associated with prognostic factors. Ann Nucl Med 26(4):345–350. https://doi.org/10.1007/s12149-012-0579-2 Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, Dankerl A, Glatting G, Reske S, Mattfeldt T (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29(10):1317–1323. https://doi.org/10.1007/s00259-002-0880-8 Caudle AS et al (2012) Local-regional control according to surrogate markers of BCsubtypes and response to neoadjuvant chemotherapy in BCpatients undergoing breast conserving therapy. BCResearch 14(3):R83 Arslan E, Çermik TF, Trabulus FDC, Talu ECK, Başaran Ş (2018) Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of 1ry breast cancer. Nucl Med Commun 39(7):680–690. https://doi.org/10.1097/MNM.0000000000000856 An Y-S, Kang DK, Jung Y, Kim TH (2017) Volume-based metabolic parameter of BCon preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis. Medicine 96(45):e8557. https://doi.org/10.1097/MD.0000000000008557 Huang J, Huang L, Zhou J, Duan Y, Zhang Z, Wang X, Huang P, Tan S, Hu P, Wang J, Huang M (2017) Elevated tumor-to-liver uptake ratio (TLR) from 18 F–FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging 44(12):1958–1968. https://doi.org/10.1007/s00259-017-3779-0 Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, Tatsumi M, Sekimoto M, Hatazawa J, Nishimura T, Monden M (2006) Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 51(12):2198–2205. https://doi.org/10.1007/s10620-006-9428-2 Kim J et al (2020) Factors affecting the negative predictive value of positron emission tomography/computed tomography for axillary lymph node staging in BCpatients. Asian Journal of Surgery 43(1):193–200 Sarikaya I, Sarikaya A (2019) Assessing PET parameters in oncologic 18F-FDG studies. Journal of Nuclear Medicine Technology 119:236109 Shi Y-M, Niu R, Shao XL, Zhang FF, Shao XN, Wang JF, Wang XS, Liu B, Yu WJ, Wang YT (2020) Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non–small cell lung cancer patients. Nucl Med Commun 41(5):459–468. https://doi.org/10.1097/MNM.0000000000001173